Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment

Vural, Suleyman; Simon, Richard; Krushkal, Julia

doi:10.1186/s40246-018-0150-x

Human Genomics

Table 3 Prevalence of mutation counts in the whole-exome sequencing data

From: Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment

		C>G		C>T		C>K		All SNV counts
Cancer type	n	Range	Mean ± SD	Range	Mean ± SD	Range	Mean ± SD	Range	Mean ± SD
BLADDER	6	5297–7790	6564 ± 968	19,570–28,590	24,077 ± 3408	24,867–36,380	30,640 ± 4373	54,376–78,947	66,878 ± 9294
BREAST	14	6141–8460	6860 ± 566	22,789–33,262	25,705 ± 2548	28,930–41,722	32,564 ± 3102	63,719–89,515	71,153 ± 6292
CESC	15	6309–7994	7095 ± 530	23,581–34,126	28,889 ± 3587	29,890–41,452	35,984 ± 3926	65,633–101,318	79,411 ± 9753
COAD/READ	16	5332–7595	6657 ± 664	20,925–36,866	25,962 ± 3970	26,257–44,461	32,620 ± 4555	59,552–89,617	70,796 ± 8093
EC	3	6703–7357	6954 ± 353	24,685–27,760	25,752 ± 1740	31,486–35,117	32,706 ± 2088	68,907–76,008	71,472 ± 3940
GLIOMA	18	5833–7682	6713 ± 458	21,183–28,151	24,924 ± 1644	27,016–35,833	31,637 ± 2096	60,001–78,102	69,420 ± 4414
HNSC	18	5195–7378	6714 ± 467	20,073–27,050	25,054 ± 1618	25,268–34,428	31,768 ± 2074	55,628–75,813	69,801 ± 4531
CLLE	42	4235–8400	6974 ± 723	17,410–32,021	26,545 ± 2888	21,645–40,010	33,520 ± 3549	47,685–86,517	72,972 ± 7267
LIHC	17	5864–8444	7007 ± 497	22,051–30,565	25,793 ± 1781	27,915–39,009	32,800 ± 2266	61,208–85,224	72,102 ± 4850
MATBCL	29	6350–8912	7209 ± 593	23,674–33,141	27,029 ± 2170	30,125–42,053	34,239 ± 2751	66,014–91,667	74,874 ± 5935
MEL	17	5722–8448	6759 ± 631	22,174–31,819	25,874 ± 2324	27,896–40,267	32,633 ± 2945	60,650–87,815	70,805 ± 6434
MESO	1	6112	6112	21,790	21,790	27,902	27,902	62,016	62,016
MM	17	6187–8662	6840 ± 628	22,773–32,455	25,456 ± 2338	28,960–41,117	32,296 ± 2961	63,335–88,898	70,785 ± 6192
NSCLC	36	5509–8739	6927 ± 768	20,710–32,767	25,641 ± 2666	26,219–41,506	32,567 ± 3424	57,506–90,159	71,563 ± 7520
OVARIAN	15	5951–7461	6682 ± 503	22,453–27,222	25,077 ± 1500	28,433–34,683	31,760 ± 1988	62,699–75,986	69,753 ± 4383
PAAD	16	5011–7432	6640 ± 588	19,327–27,658	24,801 ± 2144	24,338–35,090	31,441 ± 2725	53,010–76,653	68,905 ± 5941
PRAD	4	5699–6889	6423 ± 512	20,538–28,059	25,092 ± 3450	26,237–34,948	31,515 ± 3947	57,717–74,831	68,722 ± 8018
RCC	8	6521–7566	6980 ± 411	24,508–27,801	26,133 ± 1383	31,082–35,264	33,114 ± 1783	68,091–77,777	72,638 ± 4113
SAR	12	6336–7808	6968 ± 423	23,647–29,155	26,129 ± 1610	29,983–36,963	33,098 ± 2027	65,833–81,175	72,342 ± 4357
STAD	16	5861–7530	6807 ± 448	21,971–28,460	25,305 ± 1763	27,832–35,741	32,112 ± 2199	61,311–79,632	70,672 ± 4843
THCA	3	5811–6918	6463 ± 579	22,080–25,849	24,363 ± 2007	27,891–32,767	30,826 ± 2586	61,598–71,836	67,720 ± 5406
UCEC	2	6063–6489	6276 ± 301	24,128–24,223	24,176 ± 67	30,286–30,617	30,452 ± 234	66,406–67,542	66,974 ± 803
Pan-cancer	325	4235–8912	6865 ± 618	17,410–36,866	25,867 ± 2575	21,645–44,461	32,732 ± 3139	47,685–101,318	71,661 ± 6693

Shown are counts of C>T, C>G, and C>K substitutions on both genome strands, and of any types of SNV variants representing nucleotide substitutions
K G or T, SD standard deviation, SNV single nucleotide variant, n number of cell lines

Back to article page

ISSN: 1479-7364

Contact us

General enquiries: journalsubmissions@springernature.com